SUDOSCAN at the EASD Annual Meeting 2022


Meet Impeto Medical
at the EASD Annual Meeting 2022

Impeto Medical is pleased to announce its participation from the 19th to the 23rd of september 2022 at this year’s 58th Annual Meeting of the European Association for the Study of Diabetes (EASD Annual Meeting 2022).

Make sure to visit our booth in Hall B (Booth M.12) !

We will present our device SUDOSCAN and its efficacy in the early detection of diabetic neuropathy.

About SUDOSCAN and diabetes

  • SUDOSCAN is a quick and non-invasive test to early detect diabetic peripheral neuropathy.
  • Our device helps for a better management of diabetes complications such as diabetic foot and cardiac autonomic neuropathy.
  • SUDOSCAN can also be used during follow-up, for measuring the neuropathy evolution.


  • FAST, No patient preparation, Results in 3 minutes
  • SECURE: Non-invasive, Easy to operate, CE and FDA approvals
  • ACCURATE: Backed by evidence-based research of 200 peer-reviewed journals publications.

Click here to discover SUDOSCAN product page

About EASD Annual Meeting 2022

ASD holds its Annual Meeting in a different European city each year. More than 15,000 delegates from over 130 countries are attending this event. This event provides more than 1,200 talks and presentations on the latest results in diabetes research.
For 2022, the congress access will be hybrid and will offer the option to join in person or virtually.

How to find the EASD 2022 scientific program ?
Program overview for 2022 is available here: EASD 2022 program

Where will the EASD 2022 take place ?
Meeting venue address of the ESAD congress will be: Stockholmsmässan, Mässvägen 1, 125 30 Älvsjö, Sweden.

How to register for the EASD 2022 ?
Consult general information on the website:
For direct registration, go on the MyEASD platform

Impeto Medical

Impeto Medical


SUDOSCAN is a quick and non-invasive test that provides an accurate evaluation of sweat gland function reflecting the status of the autonomic nervous system.

With quantitative and reproducible results, SUDOSCAN allows physicians to detect early and follow-up peripheral neuropathy to monitor disease progression and assess treatment efficacy for better patient management.

SUDOSCAN efficacy has been evaluated in the assessment of small fiber neuropathies in several diseases and compared to reference tests recommended in guidelines.

Recent Posts

Subscribe to receive our scientific news


To receive our latest scientific news:

Website dedicated
to health professionals

I am a health professional

Scroll to Top